Corix Biosciences, Inc. (OTCQB: CXBS), as the first major player for applications for cancer, the opioid epidemic, and other illnesses and diseases, will patent cannabis and hemp strains for FDA approval that have direct connections to specific ailments.

CXBS just announced a major sales agreement with Positively Green Organics, LLC. (PGO) to sell up to 22,000 pounds of hemp from 150 acres of PGO’s harvest monthly.

Under the agreement, PGO will deliver their industrial hemp flower or “bud,” to one of Corix’s facilities, where Corix will package it for storage and then sell the product on the open pharmaceutical market where it can bring approximately $575 per pound. The sales of the hemp will yield Corix 34% of the gross proceeds.

Michael Ogburn, CEO of Corix Bioscience, Inc., stated, “We are very excited about this agreement and expect to generate over $50 million in revenue over the next 12 months as we are currently fielding several calls per day from purchasers of hemp, CBD oil, and raw flower.”

CXBS also recently announced that on August 1st, they moved their tissue cell culture and research divisions into a new 10,122 square foot laboratory in Carson City Nevada,  enabling them to produce over 3 million plantlets in the immediate future and 6 million in year two.

CXBS expects to sell 2.2 million of plantlets which will add $8 million in revenue.

On June 5, 2017, Corix Bioscience, Inc. (OTCQB: CXBS) announced it has signed a contract with Segra International, Inc. to build a state-of-the-art tissue culture facility in Nevada. The new facility will allow the company to begin making adjustments to cannabis seed cells and ultimately, its DNA. The goal is to create strains with greater production, stability, and higher yield. These newly developed strains is what will be patented.

About New Corix Biosciences, Inc.  

Corix Bioscience, Inc. (“Corix”) is a fully reporting SEC Wyoming corporation listed as OTCQB: CXBS. Corix is the developer of proprietary cannabis and industrial hemp strains using tissue cell cultures to propagate living plants, with plans to patent the strains to be used in the pharmaceutical medical industries.

Our methods allow us to create and breed new and existing plant strains from tissue cells free of any pathogens or disease. We grow these plants to maturity and extract the oils which are the “medicine” part of the plant. Our sales are focused towards the medical industry and we are developing brand named products to be released in early 2018.

Company headquarters are in Phoenix, AZ with our laboratory and processing facility in Carson City, NV and fields for growing the plants in Genoa, NV. We are currently looking at expanding our footprint into Washington, Oregon, California and Arizona. The Company’s mission is to create clean and consistent products in medical grade facilities. Consistency being the key which will ultimately yield a safer and superior product, better for people and the environment. For more information, please visit Corix’s website at

All information contained herein as well as on the website is obtained from sources believed to be reliable but not guaranteed to be accurate or all-inclusive. All material is for informational purposes only, is only the opinion of and should not be construed as an offer or solicitation to buy or sell securities. The information may include certain forward-looking statements, which may be affected by unforeseen circumstances and / or certain risks.  This report is not without bias. has motivation by means of either self-marketing or has been compensated by or for a company or companies discussed in this article. Full details about which can be found in our full disclosure, which can be found here,  Please consult an investment professional before investing in anything viewed within. When is long shares it will sell those shares. In addition, please make sure you read and understand the Terms of Use, Privacy Policy and the Disclosure posted on the website.

Add a Comment to this Post